Ross McNaughton, corporate technology and life sciences partner at legal firm Taylor Wessing, tracked growing optimism in the outlook for investment in life sciences assets and companies throughout 2024.
In mid-year, the UK-based partner spoke to Medtech Insight sister publication In Vivo about a sense of positivity, albeit in a still cautious environment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?